The world of small-cap health care investing is one of huge booms and major busts. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've found to be most predictive of future success, helps you find those companies with a strong foundation that are best positioned to capitalize on future success.
Here are today's top-performing health care Small-Cap Stars as of noon on the east coast:
Galena Biopharma Inc. (GALE)
Galena Biopharma Inc. gained 11.48% to $2.61 in morning trading today. Volume reached 3,457,660 by noon. The stock's average daily volume is 2,291,168 shares. Galena Biopharma Inc. has a 52-week high of $7.77 and a 52-week low of $1.66, and its 50-day SMA and 200-day SMA are $2.83 and $3.37 respectively.
Galena Biopharma Inc, is a biopharmaceutical company focused on developing and commercializing, targeted treatments that address unmet medical needs to advance cancer care.
Galectin Therapeutics Inc. (GALT)
Galectin Therapeutics Inc. gained 9.36% to $5.49 in morning trading today. Volume reached 371,018 by noon. The stock's average daily volume is 1,100,203 shares. Galectin Therapeutics Inc. has a 52-week high of $19.11 and a 52-week low of $4.28, and its 50-day SMA and 200-day SMA are $10.16 and $11.55 respectively.
Galectin Therapeutics, Inc. is a development-stage company engaged in drug research and development to create new therapies for fibrotic disease and cancer.
Erba Diagnostics (ERB)
Erba Diagnostics gained 8.17% to $3.84 in morning trading today. Volume reached 212,920 by noon. The stock's average daily volume is 82,218 shares. Erba Diagnostics has a 52-week high of $4.13 and a 52-week low of $0.77, its P/E ratio is 131.5, and its 50-day SMA and 200-day SMA are $2.30 and $2.34 respectively.
ERBA Diagnostics Inc develop, manufacture and market diagnostic test kits, and instrumentation in the areas of autoimmune, chemistry, hematology, diabetes and infectious diseases.
Cancer Genetics Inc. (CGIX)
Cancer Genetics Inc. gained 7.09% to $9.37 in morning trading today. Volume reached 135,448 by noon. The stock's average daily volume is 50,130 shares. Cancer Genetics Inc. has a 52-week high of $23.25 and a 52-week low of $8.48, and its 50-day SMA and 200-day SMA are $10.23 and $13.60 respectively.
Cancer Genetics, Inc., is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment of cancer.
Neuralstem Inc. (CUR)
Neuralstem Inc. gained 6.89% to $3.88 in morning trading today. Volume reached 775,475 by noon. The stock's average daily volume is 603,539 shares. Neuralstem Inc. has a 52-week high of $4.81 and a 52-week low of $1.55, and its 50-day SMA and 200-day SMA are $3.56 and $3.48 respectively.
Neuralstem, Inc. is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.
Equities.com's Health Care Small-Cap Stars - Helping You Build a Healthier Portfolio
There's no crystal ball that will tell you what the outcome of this or that clinical trial is going to be. Even if there were, the one astonishingly wealthy person who owns it probably wouldn't share. But that doesn't mean that investing in the right small-cap health care companies can't pay dividends in the long term. While the future of a company's lead therapy may not be certain, most of its present fundamentals are. And while investing in the small-cap biotech market will always be hit-or-miss, investing in solidly built players should help boost that batting average.
Our Small-Cap Stars system uses a complex statistical regression to isolate those fundamental factors that previous success stories had in common and then identifies those small caps that are the most similar to that profile in the present.
For health care companies, we found that a high enterprise value, a strong value line beta, and a high rate of reinvestment were among the most indicative of a small-cap company's potential for success.
All data provided by QuoteMedia and was accurate as of 12:00 pm ET.